Fisher Asset Management LLC Has $769.89 Million Holdings in Sanofi (NASDAQ:SNY)

Fisher Asset Management LLC trimmed its position in shares of Sanofi (NASDAQ:SNY) by 1.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,359,110 shares of the company’s stock after selling 239,392 shares during the quarter. Fisher Asset Management LLC owned 0.53% of Sanofi worth $769,886,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. POM Investment Strategies LLC acquired a new position in Sanofi during the second quarter worth $25,000. Northwest Investment Counselors LLC bought a new position in Sanofi in the 3rd quarter valued at about $29,000. Concord Wealth Partners boosted its stake in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the last quarter. Arrow Financial Corp bought a new stake in Sanofi during the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC raised its stake in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Trading Up 0.6 %

NASDAQ SNY opened at $48.28 on Monday. The business’s fifty day moving average is $53.70 and its 200-day moving average is $52.18. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market capitalization of $122.53 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the previous year, the firm posted $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities research analysts predict that Sanofi will post 4.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SNY. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.